|
The Drug Safety Newsletter is a FDA publication for healthcare professionals and the medical community. The newsletter provides information on the findings of selected postmarketing drug safety reviews from FDA's Center for Drug Evaluation and Research. The newsletter also provides information on important emerging drug safety issues and recently approved new molecular entities. FDA hopes the newsletter will raise awareness of reported adverse events, and stimulate additional adverse event reporting by healthcare professionals.
Postmarketing Reviews:
Mefloquine Hydrochloride: Reports of Pneumonitis
Lenalidomide: Serious Skin Reactions
Amiodarone-Simvastatin Interaction: Reports of rhabdomyolysis
Icodextrin Portable Blood Glucose Monitor Test Strip Interaction: Reports of iatrogenic, sometimes fatal, hypoglycemia
Publication of this newsletter fulfills a commitment FDA made in its January 2007 response to the Institute of Medicine's (IOM) 2006 Report on The Future of Drug Safety - Promoting and Protecting the Health of the Public.
Read the entire MedWatch 2008 Safety Summary, including a link to the FDA Drug Safety Newsletter at:
http://www.fda.gov/cder/dsn/2008_summer/toc.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
